CTX-M-14, CTX-M-24 and Resistance in Escherichia Coli and Klebsiella Pneumoniae Clinical Isolates
ZZ Xiong,DM Zhu,F Wang,YY Zhang
DOI: https://doi.org/10.1097/00029330-200601020-00012
2006-01-01
Abstract:Extended-spectrum β-lactamases (ESBLs) are the main cause of resistance to the third and forth-generation cephalosporins in Enterobacteriaceae, which are mediated by plasmids and can hydrolyze oxyiminoaminothiazolyl cephalosporins and monobactams.1 Most of ESBLs are mutants of the classical TEM and SHV types, with one or more amino-acid substitution(s) in the active site. β-lactamase inhibitors, such as clavulanic acid, can inhibit their activities. Recently, The cefotaximases (CTX-M) group, a new family of plasmid-mediated ESBLs, reported from many countries increasingly, preferentially hydrolyzes cefotaxime.2 So far, CTX-M-3 has been the most prevalent type of ESBL in China and widespread in Enterobacteriaceae, while other CTX-M type ESBLs are few reported.3 In this study, we identified the CTX-M-14 and CTX-M-24 in Klebsiella pneumoniae (K. pneumoniae) and Escherichia coli (E. coli) clinical isolates from patients in Shanghai Huashan Hospital in 1999. METHODS Antibiotic disc and antimicrobial agents Antibiotic disc and antimicrobial agents are listed as follows: cefotaxime, ceftazidime, ceftriaxone, aztreonam and amoxicillin/clavulanic acid discs (Oxoid, UK); ampicillin, cephalothin, cefuroxime, chloramphenical (Sigma, USA); piperacillin (Toyama Chemical, Japan); cefpodoxime, cefmetazole (Sankyo, Japan); cefotaxime (Aventis, Germany); ceftazidime, clavulanic acid (GlaxoSmithKline, UK); aztreonam (Eisai, Japan); cefepime (Bristol-Myer Squibb, UK); imipenem (Banyu, Japan); amikacin (Meiji Seika, Japan); gentamicin (Schering-Plough, USA); tetracycline (Wako, Japan); levofloxacin and rifampin (Daiichi Seiyaku, Japan). Bacteria, detection of ESBLs, susceptibility testing, conjugation experiments and plasmid isolation Five strains of K. pneumoniae (K99-15, 782, 809, 912, 1107) and 5 strains of E. coli (E99-533, 988, 1273, 908, 914) isolates were collected from the patients in Huashan Hospital in 1999. ESBL-producing strains were screened by the double-disk synergy test4 and confirmation test recommended by National Committee for Clinical Laboratory Standards (NCCLS).5 Antibiotic susceptibility testing was performed by agar dilution procedure5 on Mueller-Hinton agar. Results were interpreted according to NCCLS in 1999.5 Conjugation experiment was performed using E. coli K12 ÷ 1037RifRLac- as the recipient strain, all isolates as the donor strain. Transconjugants were selected on plate containing 4 mg/L cefpodoxime and 50 mg/L rifampin. ESBLs and antibiotic susceptibility were also tested in transconjugants. Plasmid extraction of donor strain and transconjugants were done by alkaline extraction method as described previously.6 Plasmid DNA was detected by agarose gel electrophoresis together with γ -Hind III DNA Markers. PCR amplification of β-lactamase partial coding genes and cloning, sequncing of entire CTX-M-13 group genes Isolates and their transconjugants were tested using TEM, SHV, CTX-M-1 group Toho-1 group, CTX-M-13 group partial coding genes by PCR method7 (Table 1). PCR was performed using a commercially available PCR kits and Takara PCR Thermal Cycler MP (Takara, Japan). The primers for amplification of entire genes from the transconjugant are shown in Table 1 (Primers contained an EcoR I restriction site and a Sac I restriction site at their 5'-ends, respectively). PCR was performed under following conditions: initial denaturation at 94 °C for 3 minutes, then 25 cycles consisting of 94 °C for 1 minute, 55 °C for 1 minute, and 72 °C for 1 minute, and finally 72 °C for 7 minutes. PCR products were shown by electrophoresis on 1.2% agarose gel. The PCR products of entire CTX-M-13 group genes from the transconjugant were purified, digested by EcoR I and Sac I (Takara, Japan), and cloned in the vector PHSG 398 by T4 ligase (Nippongene, Japan), respectively. The recombinant plasmids were transformed into the recipient E.coli K12 ÷ 1037RifRLac- by calcium chloride method, and the tansformants selected on Muelluer- \Hinton agar supplemented with 4 mg/L of cefpodoxime and 50 mg/L of chloramphenical. The presence of the insert in the plasmid was checked by restriction analysis and PCR, and dilution method was conducted again for antibiotic susceptibility of transformants. The purified PCR products of entire CTX-M-13 group genes were also sequenced on an ABI 310 automatic sequencer, and the nucleotide sequence structure was compared with the genes in GenBank.Table 1: Primers and size of PCR productMolecular typing by pulsed-field gel electrophoresis of bacterial DNA Pulsed-field gel electrophoresis (PFGE) of isolates were detected by the method described previously8 and a CHEF Mapper (Bio-Rad Laboratories, USA) for electrophoresis. Results were interpreted according to Tenover standards.9 RESULTS Resistance of clinical isolates, resistance transfer, susceptibility testing of transconjugants, and plasmid analysis All isolates were confirmed to be ESBLs producing strains and the results of antibiotic susceptibility testing are shown in Table 2. Isolates were resistant to most β-lactams and non- β-lactams, such as aminoglycosides, tetracycline. However, all the isolates were susceptible to imipenem, and most of them were also susceptible to cefmetazole and β-lactam/clavulanic acid. Transconjugants were obtained at frequency of 10-4 — 10-5 and showed positive results by double-disk synergy test. The results of susceptibility testing are also shown in Table 2. Except levofloxacin, those resistant to other non- β-lactams were cotransferred with the ESBLs of the transconjugants. Plasmid extraction and agarose electrophoresis showed that each transconjugant acquired a plasmid about >23.1 kb from its donor strain.Table 2: Antibiotic susceptibilities of K. pneumoniae, E. coli clinical isolates and their transconjugants (MIC or Breakpoint, mg/L)PCR amplification, sequencing of the CTX-M-13 group gene, susceptibility testing of transformants and results of PFGE Only CTX-M-13 group partial gene amplification products were obtained from these isolates and their transconjugants. However no amplification products were obtained with Toho-1 group specific primers. And blaTEM (E99-914, K99-809, 1107), and blaSHV (K99-15, 1107) in some isolates were not transferred. The entire coding sequences of CTX-M-13 group were amplified from the transconjugant, and PCR product of the expected size of about 1 kb were obtained and sequenced. Comparative analysis revealed that the CTX-M-13 group coding sequences were identical with those of CTX-M-14 gene (EMBL No. AF252622; 4 transconjugants: cE99-553, 988, 1273, cK99-15) or CTX-M-24 (EMBL No.AY143430; 6 transconjugants: cE99-908, cK99-782, 809, 912, 1107). The results of susceptibility testing of the transformants are shown in Table 3. According to Tenover standards, PFGE patterns of isolates of K. pneumoniae or E. coli were different from each other.Table 3: Antibiotic susceptibilities of CTX-M-13 group producing transformantsDISCUSSION Since the first discovery of CTX-M-1 ESBL in 1990,10 more than 20 different types of CTX-M ESBLs (including Toho enzymes) have been reported in different countries. The main type of CTX-M enzymes may be different in different countries. In Argentina, CTX-M-2 is more common, while Toho enzymes are common in Japan.11 In recent years, CTX-M-14 in Enterobacteriaceae has been reported from Spain, France, China, and other countries.1,12 In this study, CTX-M-14 and CTX-M-24 ESBLs were detected in clinical isolates of K. pneumoniae and E. coli from our hospital. On the other hand, CTX-M-3, 9, 11, 12, 13, 14, 15 have been reported in clinical isolates of Enterobacteriaceae from different places in China, 3,12-14 indicating the diversity of CTX-M type ESBLs in China. CTX-M-14 and CTX-M-24 enzymes were mediated by >23.1 kb plasmids and these plasmids could be transferred to the recipient strain, indicating the possibility of horizontal transfer of the resistance gene. Those plasmids may carry resistant genes of non-β-lactams, which may cause multi-drug resistance and may be cotransferred with ESBL genes to transconjugants through conjugation experiments. And blaTEM, blaSHV in some isolates were not transferred by conjugation, possibly due to chromosomal location of these genes or losing of these genes during transfer process. PFGE results showed that there was no clone spread of either CTX-M-14 or CTX-M-24 producing isolates. The homology of gene and amino acid sequence between CTX-M-24 and CTX-M-14 is about 99.9% and 99.7%, respectively. The nucleotide in protein coding region and amino acid differences between CTX-M-24 and CTX-M-14 are as follows: A823→C, Ser274 → Arg numbered in accordance with the standard by Ambler et al.15 A total of 274 amino acid residue were not important to the enzyme activity, so the resisrance pattern was the same between CTX-M-14 and CTX-M-24 producing transformants. Although CTX-M-14 and CTX-M-24 possess the70SXXK73,130 SDN132, E-166,234 KTG236 sequences that are typical of class A enzymes, it does not contain Lys-240 or Arg-240 acid residue causing ceftazidime resistance.2 The results of susceptibility testing showed that CTX-M-14 and CTX-M-24 producing transformants were resistant to most β-lactams, including cefpodoxime, cefotaxime, ceftriaxone, but they were still susceptible to ceftazidime, aztreonam, imipenem, cefmetazole and β-lactam/ β-lactamase inhibitor. Clavulanic acid may reduce the resistance of CTX-M-14 and CTX-M-24 producing transformants significantly. ESBL producing isolates are increasing.16 CTX-M type ESBLs producing isolates are common in China, which may be related to the wide use of third generation cephalosporins, especially cefotaxime. Therefore, it is important to monitor and detect such strains closely, and necessary measures must be taken to prevent their spread.